Jasper Therapeutics, Inc.
General ticker "JSPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $41.3M (TTM average)
Jasper Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -32.3%.
Estimated limits based on current volatility of 11.0%: low 0.51$, high 0.69$
Factors to consider:
- Total employees count: 64 (+42.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Dependence on key products, Regulatory and compliance, Intellectual property risks, Economic downturns and volatility
- Current price 46.8% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.00$, 3.72$]
- 2026-12-31 to 2027-12-31 estimated range: [0.95$, 3.45$]
Financial Metrics affecting the JSPR estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0.01 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term JSPR quotes
Long-term JSPR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $68.86MM | $76.24MM | $83.88MM |
| Operating Income | $-68.86MM | $-76.24MM | $-83.88MM |
| Non-Operating Income | $4.36MM | $4.97MM | $8.08MM |
| R&D Expense | $51.78MM | $55.82MM | $63.10MM |
| Income(Loss) | $-64.50MM | $-71.27MM | $-75.80MM |
| Net Income(Loss)* | $-64.47MM | $-71.27MM | $-75.80MM |
| Stockholders Equity | $78.44MM | $61.67MM | $4.15MM |
| Assets | $94.89MM | $79.90MM | $35.78MM |
| Operating Cash Flow | $-52.07MM | $-62.60MM | $-77.16MM |
| Capital expenditure | $0.27MM | $0.55MM | $0.01MM |
| Investing Cash Flow | $-0.27MM | $-0.53MM | $0.01MM |
| Financing Cash Flow | $100.97MM | $47.88MM | $34.21MM |
| Earnings Per Share** | $-6.18 | $-4.89 | $-3.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.